sm-346 and Body-Weight

Using the streptozotocin model of type 2 diabetes mellitus in Wistar rats, we compared antidiabetic activity of anxiolytic Afobazole with that of metformin. Afobazole in a dose of 10 mg/kg reduced streptozotocin-induced hyperglycemia and polyphagia and prevented accumulation of malonic dialdehyde, being not inferior to metformin in a dose of 300 mg/kg, and was even more effective than metformin in body weight recovery, elimination of polydipsia, and preservation of these effects after treatment withdrawal.

Topics: Animals; Anti-Anxiety Agents; Benzimidazoles; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Repositioning; Hyperglycemia; Hyperphagia; Hypoglycemic Agents; Male; Metformin; Morpholines; Rats; Rats, Wistar; Streptozocin

Effect of afobazole upon morphine dependency has been studied in rats upon the administration of incremental doses of morphine (10-20 mg/kg, i.p.) for 5 days. The state of dependency was evaluated by monitoring sixteen specific behavioral indices of "spontaneous" (24 h after the last morphine injection) or naloxone-induced withdrawal syndrome. The effect of afobazole (a single dose of 5 mg/kg injected before the test or subchronically for 5 days) was estimated through its influence upon the total index of withdrawal syndrome, which was calculated using the set of behavioural signs. It is established that afobazole upon either single or subchronic injections significantly decreased the expression of spontaneous morphine withdrawal syndrome. The effect was also statistically significant but less pronounced in the case of naloxone-induced withdrawal syndrome. The obtained data suggest that afobazole can be considered as potential effective drug for the correction of various clinical symptoms of morphine withdrawal syndrome.

Topics: Animals; Animals, Outbred Strains; Anti-Anxiety Agents; Behavior, Animal; Benzimidazoles; Body Weight; Drug Administration Schedule; Drug Dosage Calculations; Male; Maze Learning; Morphine; Morpholines; Motor Activity; Naloxone; Narcotic Antagonists; Narcotics; Rats; Substance Withdrawal Syndrome